ATE328000T1 - Phospholipidester von clofarabin - Google Patents

Phospholipidester von clofarabin

Info

Publication number
ATE328000T1
ATE328000T1 AT04721537T AT04721537T ATE328000T1 AT E328000 T1 ATE328000 T1 AT E328000T1 AT 04721537 T AT04721537 T AT 04721537T AT 04721537 T AT04721537 T AT 04721537T AT E328000 T1 ATE328000 T1 AT E328000T1
Authority
AT
Austria
Prior art keywords
phospholipide
clofarabine
esters
lipidesters
tumors
Prior art date
Application number
AT04721537T
Other languages
English (en)
Inventor
Dieter Herrmann
Birgit Heckl-Oestreicher
Christian Lutz
Robert Voigt
William E Bauta
Christoph Mueller
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Application granted granted Critical
Publication of ATE328000T1 publication Critical patent/ATE328000T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Plant Substances (AREA)
AT04721537T 2003-03-19 2004-03-18 Phospholipidester von clofarabin ATE328000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45600303P 2003-03-19 2003-03-19
EP03006059A EP1460082A1 (de) 2003-03-19 2003-03-19 Phospholipidester von clofarabin-derivate

Publications (1)

Publication Number Publication Date
ATE328000T1 true ATE328000T1 (de) 2006-06-15

Family

ID=33031244

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04721537T ATE328000T1 (de) 2003-03-19 2004-03-18 Phospholipidester von clofarabin

Country Status (21)

Country Link
US (1) US7419965B2 (de)
EP (2) EP1460082A1 (de)
JP (1) JP2006520359A (de)
KR (1) KR20050109939A (de)
CN (1) CN100369926C (de)
AT (1) ATE328000T1 (de)
AU (1) AU2004222163A1 (de)
CA (1) CA2519434A1 (de)
CY (1) CY1105572T1 (de)
DE (1) DE602004001047T2 (de)
DK (1) DK1606233T3 (de)
ES (1) ES2265636T3 (de)
MX (1) MXPA05008817A (de)
NO (1) NO20053903L (de)
NZ (1) NZ542011A (de)
PL (1) PL1606233T3 (de)
PT (1) PT1606233E (de)
RU (1) RU2347786C2 (de)
SI (1) SI1606233T1 (de)
WO (1) WO2004083155A2 (de)
ZA (1) ZA200507541B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070938A1 (de) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabin-Dietherphospholipid-Derivate
CN102079766A (zh) * 2009-11-29 2011-06-01 海南中化联合制药工业股份有限公司 一种单磷酸阿糖腺苷的制备方法
CN101709073B (zh) * 2009-12-01 2013-01-23 北京大学 核苷酸磷脂分子及脂质体及其制备方法和应用
CN103232510B (zh) * 2012-11-23 2015-12-23 北京大学 5’-氨基-2’,5’-双脱氧核苷酸磷脂分子及其制备方法和应用
US9771385B2 (en) * 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
KR102371969B1 (ko) 2016-12-23 2022-03-08 주식회사 엘지에너지솔루션 배터리 모듈
US12397058B2 (en) 2018-06-26 2025-08-26 Tsrl, Inc. Metabolically stable prodrugs
WO2024059754A1 (en) * 2022-09-14 2024-03-21 Quantapore, Inc. Polythiolated linkers for stable nanoparticle suspensions and uses thereof
CN122180695A (zh) * 2023-10-29 2026-06-09 玛雅生物技术有限公司 靶向端粒的磷脂酰-thio缀合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4751221A (en) 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
JPS6383094A (ja) * 1986-09-27 1988-04-13 Toyo Jozo Co Ltd エ−テル型ヌクレオシド−リン脂質複合体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
DE4321978A1 (de) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
ATE292173T1 (de) * 1994-11-12 2005-04-15 Heidelberg Pharma Gmbh Lipidspaltender enzymkomplex
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells

Also Published As

Publication number Publication date
DE602004001047T2 (de) 2007-04-19
CN100369926C (zh) 2008-02-20
CA2519434A1 (en) 2004-09-30
US7419965B2 (en) 2008-09-02
DK1606233T3 (da) 2006-09-18
KR20050109939A (ko) 2005-11-22
RU2347786C2 (ru) 2009-02-27
DE602004001047D1 (de) 2006-07-06
JP2006520359A (ja) 2006-09-07
ES2265636T3 (es) 2007-02-16
NO20053903L (no) 2005-12-19
EP1606233A2 (de) 2005-12-21
WO2004083155A3 (en) 2005-03-31
CN1771253A (zh) 2006-05-10
SI1606233T1 (sl) 2006-10-31
PL1606233T3 (pl) 2006-10-31
CY1105572T1 (el) 2010-07-28
NZ542011A (en) 2008-02-29
WO2004083155A2 (en) 2004-09-30
NO20053903D0 (no) 2005-08-22
AU2004222163A1 (en) 2004-09-30
ZA200507541B (en) 2006-05-31
PT1606233E (pt) 2006-09-29
MXPA05008817A (es) 2005-10-18
EP1460082A1 (de) 2004-09-22
EP1606233B1 (de) 2006-05-31
RU2005130992A (ru) 2006-04-10
US20060293514A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
BR0315689A (pt) Alvo para terapia de dano cognitivo
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
DE60329274D1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
DE602004024909D1 (de) Platinkomplexe zur behandlung von tumoren
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE602004020901D1 (de) System zur Einführung von mehreren Medizinprodukten
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
SE0302304D0 (sv) Novel compounds
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
SE0301650D0 (sv) Novel compounds
DE602004001047D1 (de) Phospholipidester von Clofarabin
CY1107562T1 (el) Χρηση των ν-(2-αρυλ-προπιονυλ)-σουκλφοναμιδιων για τη θepαπεια του τραυματος του νωτιαιου μυελου
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
NO20052814D0 (no) Cytomodulerende peptider for behandling av interstitielle cystitt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1606233

Country of ref document: EP

REN Ceased due to non-payment of the annual fee